Brannon John R, Hadjifrangiskou Maria
Division of Molecular Pathogenesis, Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Division of Molecular Pathogenesis, Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.
Drug Des Devel Ther. 2016 May 27;10:1795-806. doi: 10.2147/DDDT.S98939. eCollection 2016.
Pathogens deploy an arsenal of virulence factors (VFs) to establish themselves within their infectious niche. The discovery of antimicrobial compounds and their development into therapeutics has made a monumental impact on human and microbial populations. Although humans have used antimicrobials for medicinal and agricultural purposes, microorganism populations have developed and shared resistance mechanisms to persevere in the face of classical antimicrobials. However, a positive substitute is antivirulence therapy; antivirulence therapeutics prevent or interrupt an infection by counteracting a pathogen's VFs. Their application can reduce the use of broad-spectrum antimicrobials and dampen the frequency with which resistant strains emerge. Here, we summarize the contribution of VFs to various acute and chronic infections. In correspondence with this, we provide an overview of the research and development of antivirulence strategies.
病原体利用一系列毒力因子(VFs)在其感染生态位中立足。抗菌化合物的发现及其发展成为治疗药物,对人类和微生物群体产生了巨大影响。尽管人类已将抗菌药物用于医疗和农业目的,但微生物群体已发展并共享耐药机制,以在面对传统抗菌药物时得以存续。然而,一种积极的替代方法是抗毒力疗法;抗毒力治疗药物通过对抗病原体的毒力因子来预防或中断感染。它们的应用可以减少广谱抗菌药物的使用,并降低耐药菌株出现的频率。在这里,我们总结了毒力因子对各种急性和慢性感染的作用。与此相应,我们概述了抗毒力策略的研究与开发。